Brought to you by 
Israeli biotech D-Pharm completes IPO on TASE
19 Aug 2009
Executive Summary
D-Pharm (small-molecule lipid analogs) has raised NIS85mm ($23mm) in a concurrent initial public offering on the Tel Aviv Stock Exchange, which was oversubscribed and brought in NIS28mm, and a rights offering of NIS57mm. Through both financings a total of 639k shares were sold for NIS133, 13% higher than the low end of the price range.
Deal Industry
- Biotechnology
- Pharmaceuticals
Deal Status
- Final
Deal Type
-
Financing
- IPO
Already a Biomedtracker subscriber?
You have access to the full deal record through your subscription
Want to become a subscriber?
Subscribers get more deal details, updates, deal financials and deal products.
Questions?
Questions?
Please contact Sales at: (212) 520-2765 or email [email protected]
Related Companies
You must sign in to use this functionality
Authentication.SignIn.HeadSignInHeader
Israeli biotech D-Pharm completes IPO on TASE
Email Deal
All set! This article has been sent to my@email.address.
All fields are required. For multiple recipients, separate email addresses with a semicolon.
DCD.EmailPopout.Notice